Work

Cost and Coverage of Originator and Biosimilar Ustekinumab Products in Medicare Part D

Year: 2026

Type: article

Abstract: This cross-sectional study investigates the cost and coverage of ustekinumab originator Stelara and biosimilar products in 2026 for Medicare Part D.

Source: JAMA Network Open

DOI: 10.1001/jamanetworkopen.2026.31556

Authors: Grace Castle, Michael A. Carrier, Rachel E. Sachs, Nancy L. Keating, Haiden A. Huskamp, Stacie B. Dusetzina

Institutions: Vanderbilt University, Rutgers, The State University of New Jersey, Washington University in St. Louis, Harvard University

Language: English

Topic: Pharmaceutical Economics and Policy

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,000

OpenAlex ID: W7203623505

FWCI:

Cites: 1

Cited by:

Related to: